NCT00407498View on ClinicalTrials.gov

Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

September 30, 2008

Conditions
Neoplasm
Interventions
DRUG

P276-00

Starting dose of 9 mg/m2/day from day 1to 5 and day 8 to 12 in 21 day cycle.Protocol wa amended to dose the subjects for day 1 to5 in 21 day cycle after 34.4 mg/m2/day cohort.Maximum dose administered was 259 mg/m2/day

Trial Locations (3)

500082

Nizam's Institute of Medicai Sciences, Hyderabaad

L8V5C2

Juravinsky Cancer Centre, Hamilton

K7L 2V7

Kingston General Hospital, Kingston

All Listed Sponsors
lead

Piramal Enterprises Limited

INDUSTRY

NCT00407498 - Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms | Biotech Hunter | Biotech Hunter